🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Clinical Trials in Germany / NCT06977139
Recruiting Observational

Interventional Structural Registry - LuEbeck

NCT06977139 · tracked via the Priya Life Science Germany tracker
Sponsor
Prof. Dr. med. Ingo Eitel
Phase
Observational
Started
2021-09-11
Last updated
2025-05-18

Condition(s) studied

Structural Heart Disease

Study summary

The aim of the registry is to investigate the effect of catheter-assisted procedures in the context of structural heart disease on clinical morbidity and mortality. Furthermore, the long-term prognosis of patients after a catheter-based procedure is to be evaluated.

In particular, the following parameters will be documented and the following questions discussed:

* Underlying and concomitant diseases of these patients
* Evaluation of the methods in relation to the respective disease
* Safety - acute and long-term
* Effectiveness - periprocedural, hospital and long-term course
* Concomitant therapies

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Structural heart disease Exclusion Criteria: * Patients without consent/information * Age ≤ 18 years

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Universitätsklinikum Schleswig-Holstein Lübeck Schleswig-Holstein Recruiting

More Prof. Dr. med. Ingo Eitel trials in Germany

The GErman Italian Spanish Takotsubo (GEIST) Registry Recruiting
Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy Recruiting
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension Recruiting
MYVAL Transcatheter Heart Valve System - Prospective German Multicenter Registry Recruiting
Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06977139 on ClinicalTrials.gov ↗ ← All trials in Germany